Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases May 25, 2021
Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential April 27, 2021
Armed with Pfizer’s ADC Platform, Pyxis Scores $152M Round to Shoot for the Clinic while Taking its Time on I/O Programs April 2, 2021
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics March 30, 2021
